By: Rahul Koul
Last updated : April 14, 2026 3:58 pm
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
At India Pharma 2026 event in New Delhi, Dr Sanjay Singh, Chief Executive Officer of Gennova Biopharmaceuticals struck an optimistic note on the future of India’s biologics and innovation ecosystem, highlighting the importance of talent, regulatory agility, and policy support.
Singh said that having experienced industry talent on board is a major advantage as India strengthens its capabilities in advanced therapeutics. He noted that while capacity and capability constraints at DCGI have become visible in recent years, new initiatives such as Biopharma Shakti are steps in the right direction and could help accelerate sectoral growth.
He emphasized that serious innovation backed by strong data will naturally receive faster review and approval support from ICMR, reflecting the growing maturity of India’s scientific and regulatory framework.
Pointing to the global pace of innovation, Singh noted that the US FDA approved 55 new products last year, underscoring the scale of opportunity for Indian companies to move beyond conventional drug development.
He also stressed that generic medicines must be viewed separately from biologics, given the complexity, regulatory pathways, and scientific rigor involved in developing biological therapies.
Calling it a developing story for India’s life sciences sector, Singh said the industry is likely to witness a wave of new innovations in the coming years.
“We will see a lot of innovations coming up soon. I am very positive about it,” he said.
India Pharma 2026 was held by Department of Pharmaceuticals, FICCI and IPA in New Delhi on 13-14 April, 2026.